{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:43:26Z","timestamp":1780490606859,"version":"3.54.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,27]]},"abstract":"<jats:p>\n                    Dedifferentiated liposarcoma (DDLPS) represents a high-grade sarcoma characterized by transition from well-differentiated liposarcoma to non-lipogenic sarcoma. Population-based data examining prognostic factors and treatment outcomes remain limited. This study aimed to identify predictors of survival and evaluate treatment modalities in patients with DDLPS using the Surveillance, Epidemiology, and End Results database. We identified 3962 patients diagnosed with DDLPS between 2000 to 2022 from the Surveillance, Epidemiology, and End Results database. Patient demographics, tumor characteristics, treatment modalities, and survival outcomes were analyzed. Cox proportional hazards regression models were utilized to identify independent prognostic factors for overall survival (OS) and cancer-specific survival. The cohort had a median age of 66 years (interquartile range 57\u201375), with male predominance (67.5%). Primary tumors were predominantly located in soft tissues (51.4%) and retroperitoneum (36.1%). The median tumor size was 145mm (interquartile range 82\u2013220\u2009mm). Surgery was performed in 85.4% of patients, while radiation therapy and chemotherapy were administered to 33.5% and 18.2%, respectively. Median OS was 54.0 months with 1-year, 2-year, 3-year, and 5-year survival rates of 78.8% (95% confidence intervals [CIs]: 77.5\u201380.1%), 67.9% (95% CI: 66.4\u201369.4%), 59.6% (95% CI: 58.0\u201361.3%), and 47.6% (95% CI: 45.8\u201349.4%), respectively. In multivariate analysis including 1507 patients with complete staging data, independent predictors of worse OS included advanced age (hazard ratios [HR]\u2005=\u20051.42 per 10 years, 95% CI: 1.34\u20131.50,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.0001), regional stage (HR\u2005=\u20051.30, 95% CI: 1.13\u20131.48,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.05), distant stage (HR\u2005=\u20052.45, 95% CI: 2.02\u20132.97,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.0001), and increasing tumor size (HR\u2005=\u20051.01 per cm, 95% CI: 1.01\u20131.01,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.0001). Surgical resection conferred significant survival benefit (HR\u2005=\u20050.29, 95% CI: 0.23\u20130.36,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.0001), as did radiation therapy (HR\u2005=\u20050.75, 95% CI: 0.66\u20130.86,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.0001). Paradoxically, chemotherapy was associated with worse survival (HR\u2005=\u20051.42, 95% CI: 1.20\u20131.69,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.0001). Retroperitoneal location demonstrated worse prognosis compared to non-retroperitoneal sites (median OS: 46.0 vs 60.0 months, log-rank\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.0001; median cancer-specific survival: 84.0 vs 122.0 months, log-rank\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.0001). This large population-based analysis demonstrates that surgical resection remains the cornerstone of treatment for DDLPS, providing substantial survival benefit. Advanced stage, older age, and larger tumor size independently predict poor outcomes. The adverse association with chemotherapy likely reflects selection bias, with systemic therapy reserved for aggressive or advanced disease.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000047738","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T01:00:25Z","timestamp":1772240425000},"page":"e47738","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Predictors of survival in dedifferentiated liposarcoma: A population-based analysis of the SEER database"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4666-5118","authenticated-orcid":false,"given":"Akef","family":"Obeidat","sequence":"first","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh, Saudi Arabia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260413","first-page":"263","article-title":"Dedifferentiated liposarcoma.","volume":"18","author":"Nascimento","year":"2001","journal-title":"Semin Diagn Pathol"},{"key":"R2-20260413","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00000478-197912000-00004","article-title":"Liposarcoma A study of 55 cases with a reassessment of its classification.","volume":"3","author":"Evans","year":"1979","journal-title":"Am J Surg Pathol"},{"key":"R3-20260413","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.path.2015.05.007","article-title":"Diagnostically challenging spindle cell neoplasms of the retroperitoneum.","volume":"8","author":"Schaefer","year":"2015","journal-title":"Surg Pathol Clinics"},{"key":"R4-20260413","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1097\/01.pas.0000170343.09562.39","article-title":"MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data.","volume":"29","author":"Binh","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"R5-20260413","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cancergen.2017.09.005","article-title":"High amplification levels of MDM2 and CDK4 correlate with poor outcome in patients with dedifferentiated liposarcoma: a cytogenomic microarray analysis of 47 cases.","volume":"218-219","author":"Ricciotti","year":"2017","journal-title":"Cancer Genet"},{"key":"R6-20260413","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00428-009-0815-x","article-title":"Well-differentiated and dedifferentiated liposarcomas.","volume":"456","author":"Coindre","year":"2010","journal-title":"Virchows Arch"},{"key":"R7-20260413","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1186\/s12885-025-13813-w","article-title":"Clinical course and prognostic factors of patients with dedifferentiated liposarcoma: a retrospective analysis.","volume":"25","author":"Casier","year":"2025","journal-title":"BMC Cancer"},{"key":"R8-20260413","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1097\/CORR.0000000000001338","article-title":"What are the results of resection of localized dedifferentiated liposarcomas in the extremities?","volume":"478","author":"Nakata","year":"2020","journal-title":"Clin Orthop Relat Res"},{"key":"R9-20260413","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12957-024-03552-w","article-title":"Efficacy of surgery in the management of multiple recurrences of retroperitoneal dedifferentiated liposarcoma.","volume":"22","author":"Yamada","year":"2024","journal-title":"World J Surg Oncol"},{"key":"R10-20260413","doi-asserted-by":"crossref","first-page":"891710","DOI":"10.3389\/fonc.2022.891710","article-title":"A systematic review of margin status in retroperitoneal liposarcomas: does the R0 margin matter?","volume":"12","author":"Paik","year":"2022","journal-title":"Front Oncol"},{"key":"R11-20260413","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.soc.2016.05.007","article-title":"Liposarcoma: multimodality management and future targeted therapies.","volume":"25","author":"Crago","year":"2016","journal-title":"Surg Oncol Clin N Am"},{"key":"R12-20260413","doi-asserted-by":"crossref","first-page":"11836","DOI":"10.1038\/s41598-017-12132-w","article-title":"Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard.","volume":"7","author":"Livingston","year":"2017","journal-title":"Sci Rep"},{"key":"R13-20260413","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.ejso.2015.01.012","article-title":"Metastasis in dedifferentiated liposarcoma: predictors and outcome in 148 patients.","volume":"41","author":"Tirumani","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"R14-20260413","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/SLA.0000000000000869","article-title":"Lessons learned from the study of 10,000 patients with soft tissue sarcoma.","volume":"260","author":"Brennan","year":"2014","journal-title":"Ann Surg"},{"key":"R15-20260413","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jos.2018.06.008","article-title":"Liposarcoma: clinico-pathological analysis, prognostic factors and survival in a series of 307 patients treated at a single institution.","volume":"23","author":"Muratori","year":"2018","journal-title":"J Orthop Sci"},{"key":"R16-20260413","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.ejso.2018.03.028","article-title":"Differences in recurrence and survival of extremity liposarcoma subtypes.","volume":"44","author":"Vos","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"R17-20260413","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1245\/s10434-007-9805-x","article-title":"Resectable well-differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches.","volume":"15","author":"Lahat","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"R18-20260413","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1200\/JCO.2017.74.9598","article-title":"Clinical and molecular spectrum of liposarcoma.","volume":"36","author":"Lee","year":"2018","journal-title":"J Clin Oncol"},{"key":"R19-20260413","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.3390\/cancers14174091","article-title":"Surgical principles of primary retroperitoneal sarcoma in the era of personalized treatment: a review of the frontline extended surgery.","volume":"14","author":"Munoz","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R20-20260413","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.cireng.2019.10.010","article-title":"Update in pelvic and retroperitoneal sarcoma management: the role of compartment surgery.","volume":"97","author":"Pascual","year":"2019","journal-title":"Cirug\u00eda Espa\u00f1ola (English Edition)"},{"key":"R21-20260413","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3389\/fonc.2024.1432900","article-title":"Comprehensive treatment strategy for improving surgical resection rate of retroperitoneal sarcomas: a histology-specific approach narrative review.","volume":"14","author":"Garcia-Ortega","year":"2024","journal-title":"Front Oncol"},{"key":"R22-20260413","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S1470-2045(20)30446-0","article-title":"Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial.","volume":"21","author":"Bonvalot","year":"2020","journal-title":"Lancet Oncol"},{"key":"R23-20260413","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2012.46.5476","article-title":"Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.","volume":"31","author":"Dickson","year":"2013","journal-title":"J Clin Oncol"},{"key":"R24-20260413","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1200\/JCO.21.01829","article-title":"Selinexor in advanced, metastatic dedifferentiated liposarcoma: a multinational, randomized, double-blind, placebo-controlled trial.","volume":"40","author":"Gounder","year":"2022","journal-title":"J Clin Oncol"},{"key":"R25-20260413","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/annonc\/mdz124","article-title":"Surgery in reference centers improves survival of sarcoma patients: a nationwide study.","volume":"30","author":"Blay","year":"2019","journal-title":"Ann Oncol"},{"key":"R26-20260413","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejca.2017.02.005","article-title":"A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.","volume":"76","author":"de Jonge","year":"2017","journal-title":"Eur J Cancer"},{"key":"R27-20260413","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1002\/cncr.30726","article-title":"T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.","volume":"123","author":"Pollack","year":"2017","journal-title":"Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047738","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T16:01:25Z","timestamp":1776096085000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047738","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"2025-11-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}